title: Successful treatment with reduced-intensity stem cell transplantation for secondary myelofibrosis following polycythemia vera.
abstract: Ten years after being diagnosed with polycythemia vera, a 55-year-old woman required frequent blood transfusion due to secondary myelofibrosis. She underwent reduced-intensity stem cell transplantation (RIST) from an HLA-identical sibling donor. Since mixed chimerae were identified in the peripheral blood at day 35, cyclosporine was withdrawn. At day 73, she developed acute graft-versus-host disease of the liver, while simultaneous resolution of splenomegaly occurred and complete donor chimerism in the peripheral blood was achieved. Frequent red blood cell transfusion was required until day 300 after transplantation. Thus, RIST for an older patient with secondary myelofibrosis was successful without severe treatment-related morbidity. This case suggests that RIST could be an effective treatment modality for secondary myelofibrosis.
authors.affiliation: Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine.
authors.forename: Kenichi
authors.initials: K
authors.lastname: TAHARA
authors.forename: Akihiko
authors.initials: A
authors.lastname: YOKOHAMA
authors.forename: Hiroshi
authors.initials: H
authors.lastname: HANDA
authors.forename: Takayuki
authors.initials: T
authors.lastname: SAITOH
authors.forename: Hideki
authors.initials: H
authors.lastname: UCHIUMI
authors.forename: Tomomi
authors.initials: T
authors.lastname: SEKIGAMI
authors.forename: Kohtaro
authors.initials: K
authors.lastname: TOYAMA
authors.forename: Momoko
authors.initials: M
authors.lastname: MAWATARI
authors.forename: Yohei
authors.initials: Y
authors.lastname: OSAKI
authors.forename: Takafumi
authors.initials: T
authors.lastname: MATSUSHIMA
authors.forename: Masamitsu
authors.initials: M
authors.lastname: KARASAWA
authors.forename: Hirokazu
authors.initials: H
authors.lastname: MURAKAMI
authors.forename: Norifumi
authors.initials: N
authors.lastname: TSUKAMOTO
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: NOJIMA
mesh_terms: D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D011087:Polycythemia Vera / Q000150:complications*; D055728:Primary Myelofibrosis / Q000209:etiology* / Q000628:therapy*; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D053614:Janus Kinase 2; D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan